Korro Bio Company
OPERA™ platform using oligonucleotides to make precise, single-base edits to RNA; a modality-focused company.
Connections from
Founded Date:
2018
Employee Number:
11-50
Last Funding Type:
Series A
Headquarters:
USA
Total Funding:
> $200 M (Public via merger)
Funding Status:
Early Stage Venture
Industry:
PharmTech